NCT06005038 is a Phase 1 clinical trial of pSOPT in Mild Cognitive Impairment, sponsored by Stanford University.

Who is sponsoring NCT06005038?

NCT06005038 is sponsored by Stanford University.

What drugs are being tested in NCT06005038?

Interventions in NCT06005038: pSOPT, MLA.

What condition does NCT06005038 study?

NCT06005038 studies Mild Cognitive Impairment, Subjective Cognitive Impairment.

Is NCT06005038 still recruiting?

NCT06005038 is currently recruiting now. Last updated 17 May 2024.

Last reviewed 2024-05-17 · How we verify

NCT06005038

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CogT pSOPT Intervention Study

Recruiting now Phase 1 Last updated 17 May 2024

What this trial tests

Phase 1 trial testing pSOPT in Mild Cognitive Impairment in 50 participants. Currently enrolling.

Timeline

12 January 2024

Primary endpoint
1 December 2026

31 December 2026

Quick facts

Lead sponsor	Stanford University
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	50
Start date	12 January 2024
Primary completion	1 December 2026
Estimated completion	31 December 2026
Sites	1 location across United States

Drugs / interventions tested

pSOPT
MLA

Conditions studied

Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
Subjective Cognitive Impairment — all drugs for Subjective Cognitive Impairment →

Sponsor

Stanford University

Who can join

60 and older, any sex, with Mild Cognitive Impairment or Subjective Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

(JUSTIFICATION: This is the R33 stage of an NIH funded R21/R33 study. R21 stage (IRB-61727) was focused on intervention development; R33 stage will focus on pilot testing the effect of the intervention. The R21 phase was not considered a NIH defined clinical trial; R33 will be considered a NIH defined clinical trial) The purpose is to develop and test the effect of a "personalized" computer-based cognitive training program. The personalized program tailors the difficulty of the training tasks using a participant's biofeedback (i.e., heart rate) and cognitive performance. Such a personalization will ensure that the participant can perform at his/her ideal training capacity. Participants will be randomized into one of 2 groups and each group will play a different version of computerized training game and have ECG collected to allow subject blinding.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Mild Cognitive Impairment

Currently open trials in the same condition.

NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06005038 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 17 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06005038.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing